Delving into the Latest Updates on Alpha-Beta Technology, Inc. with Synapse

概览

疾病领域	数量

肿瘤	2

排名前五的药物类型	数量

小分子化药	1
单克隆抗体	1

排名前五的靶点	数量

αvβ3(整合素α-V/β-3复合体)	1

关联

2

项与 Alpha-Beta Technology, Inc. 相关的药物

PGG-Glucan (Alpha-Beta Technology, Inc.)

靶点-

作用机制

免疫调节剂

在研机构

Alpha-Beta Technology, Inc. [+1]

原研机构

Alpha-Beta Technology, Inc.

在研适应症

结直肠癌

非在研适应症

难治性慢性淋巴细胞白血病

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

ABT101(Alpha Beta Therapeutics)

靶点

αvβ3

作用机制

αvβ3拮抗剂

在研机构

University of California San Diego [+1]

原研机构

University of California San Diego [+1]

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Alpha-Beta Technology, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Alpha-Beta Technology, Inc. 相关的专利（医药）

登录后查看更多信息

21

项与 Alpha-Beta Technology, Inc. 相关的文献（医药）

1999-08-20·ACS Symposium Series

Application of Multi-Detector SEC with a Post Column Reaction System: Conformational Characterization of PGG-Glucans

作者: Park, J. T. ; Guo, Y. A. ; Ostroff, G. R. ; Magee, A. S.

Multi-detector Size Exclusion Chromatog. (SEC) with several post column reaction systems has been used to characterize the conformation of PGG-Glucans.PGG-Glucans are β(1→3) glucans isolated from the yeast cell wall (saccharomyces cerevisiae).Three conformational aspects of PGG-Glucans were characterized: (1) Single Chain (SC) conformation, (2) Triple Helical (TH) conformation, and (3) Triple Helical aggregates.PGG-Glucans were separated by SEC and analyzed using the refractive index, multi-angle laser light scattering, fluorescence, and polarimeter in combination with the post column reaction system.The Single Chain conformation was detected and characterized using SEC followed by Aniline Blue (AB) post column reaction system and using SEC coupled with polarimetric detection.The Triple Helical conformation was characterized using SEC coupled with polarimetry and sodium hydroxide post column reaction system.The Triple Helical aggregate was characterized using multi-detector SEC with and without sodium hydroxide post column reaction system.The Aggregate Number Distribution (AND) of PGG-Glucans across the entire mol. weight range was determinedThe AND for Triple Helical PGG-Glucan ranged from 3 to over 10.These results indicate that PGG-Glucan forms aggregate of triple helical structure in aqueous solution

1999-06-01·The Journal of Immunology2区 · 医学

Promotion of Neutrophil Chemotaxis Through Differential Regulation of β1 and β2 Integrins

2区 · 医学

作者: Reichner, Jonathan S. ; Wakshull, Eric ; Albina, Jorge E. ; Harler, Mary Beth ; Filardo, Edward J.

AbstractMigration of neutrophils requires sequential adhesive and deadhesive interactions between β1 and β2 integrins and components of the extracellular matrix. Prompted by reports that describe interaction of soluble β-glucan with the β2 integrin Mac-1, a role for β-glucan in regulation of integrin-mediated migration was investigated. Neutrophil migration in response to fMLP was assessed using an agarose overlay method with slides precoated with fibronectin (Fn) ± β-glucan. On Fn, random migration in excess of directed migration was observed. In contrast, migration on Fn + β-glucan was directional, with marked diminution of random migration. This conversion of random to directed migration was seen neither when Fn was supplemented with alternative polysaccharides nor when β-glucan was applied to other components of the extracellular matrix. This effect of β-glucan was shown to be cation dependent and to be effected by Arg-Gly-Asp-containing peptides consistent with an integrin-mediated event. mAb inhibition studies demonstrate that β-glucan effects this shift toward directed migration through suppression of migration mediated by Mac-1 and very late Ag 5 and enhancement of very late Ag 3-mediated migration. Adhesion assays suggest that the prochemotactic influence of β-glucan is due, in part but not entirely, to modulation of PMN adhesion to Fn. In summary, these data support a novel role for β-glucan in regulation of β1- and β2-mediated neutrophil migration on Fn.

1998-12-01·IDrugs : the investigational drugs journal

MAK-195F Knoll AG.

Article

作者: Mackin, W M

BASF is developing the monoclonal antibody MAK-195F, a tumor necrosis factor (TNF)-alpha antagonist, for the potential treatment of septic shock. It is in phase III clinical trials in the US and Europe [198973]. Results from the trials were expected between late 1997 and early 1998 [200089], but none have yet been reported. Launch of the drug was expected in 2000 [277817]. Results from a phase II clinical trial on 122 patients in Germany did not show prolonged survival in patients with septic shock but did indicate lowered levels of IL-6. The treatment was well-tolerated [222840]. A patent disclosing similar human antibodies that bind to TNF was published by BASF in August 1997 (WO-09729131).

100 项与 Alpha-Beta Technology, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Alpha-Beta Technology, Inc. 相关的转化医学

登录后查看更多信息